Paper Details

  1. Home
  2. Paper Details

Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.

Author: CairoliRoberto, DeodatoMarina, FrustaciAnna M, MontilloMarco, TedeschiAlessandra, ZamprognaGiulia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Duvelisib is a dual phosphoinositide-3-kinase inhibitor targeting p110-δ/γ that has been approved for relapsed/refractory chronic lymphocytic leukemia. While effective, immune-related effects often lead to treatment suspension.
Paper Details　
Original Abstract of the Article :
P110-γ and -δ act in lymphocytes chemotaxis, presenting distinct, nonredundant roles in B- and T-cell migration and adhesion to stromal cells. Moreover, phosphoinositide-3-kinase-γ inhibition contributes to regulate macrophage polarization inhibiting cancer growth. Duvelisib (IPI-145) is an oral fir...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2018-0881

データ提供：米国国立医学図書館（NLM）

Duvelisib: A New Weapon in the Fight Against Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL), a type of blood cancer, is as persistent as a desert sand dune, slowly encroaching on the body's defenses. This review explores the potential of duvelisib, a novel phosphoinositide-3-kinase inhibitor, in treating relapsed/refractory CLL, offering a new weapon in the fight against this challenging disease, much like a desert traveler discovering a hidden oasis of effective remedies.

A Promising New Treatment

This review discusses the mechanism of action of duvelisib, highlighting its unique ability to target specific enzymes involved in the growth and survival of CLL cells. The review also examines the results of clinical trials, demonstrating duvelisib's effectiveness in extending progression-free survival and improving overall response rates in patients with relapsed/refractory CLL. This research provides a glimmer of hope for patients struggling with this challenging disease, much like a desert traveler finding a source of water in a seemingly barren landscape.

Navigating the Side Effects

This review also acknowledges the potential side effects of duvelisib, a reminder that even the most promising treatments can come with challenges. It's like a desert traveler facing the risks and rewards of venturing into uncharted territory. The review emphasizes the importance of careful monitoring and management of side effects, ensuring the best possible outcomes for patients.

Dr.Camel's Conclusion

Duvelisib represents a promising new treatment for chronic lymphocytic leukemia, offering a much-needed oasis in the desert of this challenging disease. This review provides valuable insights into the drug's potential and its limitations, highlighting the importance of ongoing research and careful patient management in the fight against this formidable foe.
Date :
  1. Date Completed 2019-12-18
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

31137964

DOI: Digital Object Identifier

10.2217/fon-2018-0881

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.